Affiliation:
1. Kantar, Health Division, New York, NY 10007, USA
2. GlaxoSmithKline, Philadelphia, PA 19426, USA
Abstract
Aim: To report the results of a patient epidemiology model for multiple myeloma (MM) treatment by line of therapy (LOT) in the USA. Materials & methods: Surveillance, Epidemiology and End Results registry data and physician surveys were combined to project the incidence, prevalence and the number of MM patients treated with systemic therapy by LOT between 2020 and 2025. Results: Projected complete MM prevalence in the USA in 2020 was 144,922, increasing to 162,339 in 2025. Corresponding unique MM patients by LOT in 2020 were: 53,176 (1st; minimum–maximum: 47,304–59,212), 19,407 (2nd; 15,935–23,273), 6,481 (3rd; 5143–8877), 1649 (4th; 1146–2667) and 426 (5th; 217–876). Conclusion: MM incidence and prevalence by LOT is projected to continue to increase in the USA between 2020 and 2025.
Subject
Cancer Research,Oncology,General Medicine
Reference23 articles.
1. National Cancer Institute. Plasma cell neoplasms (including multiple myeloma). National Cancer Institute (2019).https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq
2. Multiple Myeloma
3. American Cancer Society. Cancer facts and figures 2019 Atlanta. American Cancer Society, GA, USA (2019).https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html
4. Recent major improvement in long-term survival of younger patients with multiple myeloma
5. National Cancer Institute. Drugs approved for multiple myeloma and other plasma cell neoplasms. National Cancer Institute (2019).https://www.cancer.gov/about-cancer/treatment/drugs/multiple-myeloma
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献